GRAL
107.97USD
+27.20 (+33.68%)
52-week high $118.84
52-week low $41.50
GRAIL stock jumped 33.7 percent while the Nasdaq gained just 2.3 percent, meaning it far outpaced the broader market. Fresh FDA signals on the company's Galleri cancer-detecting blood test raised approval hopes and sparked the rally. Trading reached 3.5 times its average as investors reacted to the news.
FDA papers lift Galleri approval hopes
GRAIL Stock Jumped 34% Yesterday. The FDA Just Told Its Investors Why.
GRAL Stock Clocks Best Day In Over 1.5 Years — FDA Papers Lift Galleri Approval Hopes
Grail Catapults 30%-Plus As FDA Mulls Cancer-Detecting Blood Test
FDA Decision Watch: MRK, MIRM, INCY, GRAL Face Key Regulatory Catalysts This Week
The company is still unprofitable (net income is negative).
The core business is losing money at the operating line.
Price is 34% above the 1-month average and 46% above the 3-month average — recent trend is up.
Over the last 3 months it is about 57% ahead of the market — a leading move.
Buying momentum has picked up over the last few days.
The recent run looks stretched — a pause would not be surprising.
Today's is 3.5x the 20-day average and the stock is up — buyers are showing up.
has been rising (5-day avg is 2.2x the 20-day) and the stock is up — accumulation.
A single day's movement doesn't change the long-term direction.
It's okay not to decide right now.
This content is compiled from publicly available data for reference only. It is not investment advice or a stock recommendation. All investment decisions and their outcomes are your own responsibility.